AngioGenex, Inc. operates as a biopharmaceutical company, which engages in developing and commercializing novel platform of anti-proliferative drugs for the treatment of cancer and macular degeneration. The company was founded by Michael M. Strage and Robert Benezra on March 31, 1999 and is headquartered in New York, NY.
Company profile
Ticker
AGGX
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ECLIC INC/NV
SEC CIK
Corporate docs
IRS number
860945116
AGGX stock data
Latest filings (excl ownership)
REVOKED
Registration or securities revoked
10 Mar 23
D
$260K in debt / options, sold $260K, 1 investor
17 Dec 21
8-K
Entry into a Material Definitive Agreement
16 Dec 21
8-K
Departure of Directors or Certain Officers
13 Jul 20
8-K
Entry into a Material Definitive Agreement
11 Feb 20
8-K
Departure of Directors or Certain Officers
13 Sep 19
10-Q
2019 Q2
Quarterly report
14 Aug 19
10-Q
2019 Q1
Quarterly report
20 May 19
NT 10-Q
Notice of late quarterly filing
15 May 19
DEF 14A
Definitive proxy
1 Apr 19